UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
Commission file number
(Exact Name of Registrant as Specified in Its Charter)
| ||
(State or Other Jurisdiction of Incorporation or Organization) | (I.R.S. Employer Identification No.) | |
(Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code:
(
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
| Accelerated filer ☐ | ||
Non-accelerated filer ☐ | Smaller reporting company | |||
Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes
As of July 31, 2025, there were
Safe Harbor Statement
This quarterly report on Form 10-Q (the “Report”) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, relating to Veeco Instruments Inc. (together with its consolidated subsidiaries, “Veeco,” the “Company,” “Registrant,” “we,” “our,” or “us,” unless the context indicates otherwise) that are based on management’s expectations, estimates, projections, and assumptions. When used in this Report, the words such as “expects,” “anticipates,” “plans,” “believes,” “scheduled,” “estimates,” and variations of these words and similar expressions are intended to identify forward-looking statements. Discussions containing such forward-looking statements may be found in Part I - Items 1, 2, and 3 hereof, as well as within this Report generally.
In addition, the preparation of financial statements in conformity with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although these estimates and assumptions are based on knowledge of current events and planned actions to be undertaken in the future, they may ultimately differ from actual results. Operating results for the three and six months ended June 30, 2025 are not necessarily indicative of the results that may be expected for the year ending December 31, 2025. All estimates and assumptions are subject to a number of risks and uncertainties that could cause actual results to differ materially from these estimates and assumptions.
Forward-looking statements in this discussion include, but are not limited to, those regarding anticipated growth and trends in our business and markets, industry outlooks and demand drivers, our investment and growth strategies, our development of new products and technologies, our business outlook for the current and future periods, and other statements that are not historical facts. Factors that could cause actual results to differ materially from those expressed or implied by such statements include, without limitation, those set forth under the heading “Risk Factors” in Part 1, Item 1A of our 2024 Form 10-K, and the following:
● | Changes in U.S. and foreign trade policies, including the recent imposition of tariffs, together with the prospect of additional foreign and domestic trade restrictions; |
● | Risks associated with operating a global business, including ongoing trade disputes between the U.S. and China; |
● | An inability to obtain required export licenses for the sale of our products; |
● | Unfavorable market conditions; |
● | Significant third party competition; |
● | Risks associated with operating in industries characterized by rapid technological change; |
● | Our dependency on the demand for consumer electronic products and automobiles; |
● | Our concentrated customer base; |
● | The cyclicality of the industries we serve; |
● | A failure to estimate customer demand accurately; |
● | Our reliance on a limited number of suppliers, some of whom are our sole source for particular components; |
1
● | A failure to successfully manage our outsourcing activities or a failure of our outsourcing partners to perform as anticipated; |
● | The timing of our orders, shipments, and revenue recognition; |
● | Our long and unpredictable sales cycles; |
● | Customer order cancellations or modifications; |
● | Risks associated with business combinations, acquisitions, strategic investments and divestitures; |
● | Risks associated with global regulatory requirements; |
● | Disruptions in our information technology systems or data security incidents; |
● | An inability to effectively enforce and protect our intellectual property rights; |
● | Claims of intellectual property infringement by others; |
● | Tightening credit markets; |
● | Foreign currency exchange risks; |
● | Asset impairment charges; |
● | Changes in accounting pronouncements or taxation rules, practices, or rates; |
● | Restrictions, covenants and repurchase provisions appearing in our current debt facilities; |
● | Possible impairment to our ability to utilize our research and development credits carryforwards caused by the issuance of common stock upon the conversion of the Notes; |
● | Our capped call transactions, which may affect the value of our common stock; |
● | An inability to attract, retain, and motivate employees; |
● | Risks associated with non-compliance with environmental, health, and safety regulations; |
● | Environmental, social and governance goals, strategies and requirements which could be costly to implement and which expose us to risks associated with failures to comply; |
● | Measures adopted by Veeco which may have anti-takeover effects or which may make an acquisition of our Company by another company more difficult; and |
● | Other risks and uncertainties described in our SEC filings on Forms 10-K, 10-Q, and 8-K, and from time-to-time in our other SEC reports. |
All forward-looking statements speak only to management’s expectations, estimates, projections and assumptions as of the date of this filing or, in the case of any document referenced herein or incorporated by reference, the date of that document. The Company does not undertake any obligation to update or publicly revise any forward-looking statements to reflect events, circumstances or changes in expectations after the date of this filing.
2
PART I—FINANCIAL INFORMATION
Item 1. Financial Statements
Veeco Instruments Inc. and Subsidiaries
Consolidated Balance Sheets
(in thousands, except share amounts)
June 30, | December 31, | |||||
| 2025 |
| 2024 | |||
Assets | (unaudited) | |||||
Current assets: | ||||||
Cash and cash equivalents | $ | | $ | | ||
Restricted cash | | | ||||
Short-term investments |
| |
| | ||
Accounts receivable, net |
| |
| | ||
Contract assets | | | ||||
Inventories |
| |
| | ||
Prepaid expenses and other current assets | | | ||||
Total current assets |
| |
| | ||
Property, plant, and equipment, net |
| |
| | ||
Operating lease right-of-use assets | | | ||||
Intangible assets, net | | | ||||
Goodwill |
| |
| | ||
Deferred income taxes | | | ||||
Other assets |
| |
| | ||
Total assets | $ | | $ | | ||
Liabilities and stockholders' equity | ||||||
Current liabilities: | ||||||
Accounts payable | $ | | $ | | ||
Accrued expenses and other current liabilities |
| |
| | ||
Contract liabilities |
| |
| | ||
Income taxes payable |
| |
| | ||
Current portion of long-term debt |
| — |
| | ||
Total current liabilities |
| |
| | ||
Deferred income taxes |
| |
| | ||
Long-term debt |
| |
| | ||
Long-term operating lease liabilities | | | ||||
Other liabilities |
| |
| | ||
Total liabilities |
| |
| | ||
Stockholders' equity: | ||||||
Preferred stock, $ |
| |||||
Common stock, $ |
| |
| | ||
Additional paid-in capital |
| |
| | ||
Accumulated deficit |
| ( |
| ( | ||
Accumulated other comprehensive income |
| |
| | ||
Total stockholders' equity |
| |
| | ||
Total liabilities and stockholders' equity | $ | | $ | |
See accompanying Notes to the Consolidated Financial Statements.
3
Veeco Instruments Inc. and Subsidiaries
Consolidated Statements of Operations
(in thousands, except per share amounts)
(unaudited)
Three months ended June 30, | Six months ended June 30, | ||||||||||||
| 2025 |
| 2024 |
| 2025 |
| 2024 |
| |||||
Net sales | $ | | $ | | $ | | $ | | |||||
Cost of sales |
| |
| |
| |
| | |||||
Gross profit |
| | | | | ||||||||
Operating expenses, net: | |||||||||||||
Research and development |
| |
| |
| |
| | |||||
Selling, general, and administrative |
| |
| |
| |
| | |||||
Amortization of intangible assets |
| |
| |
| |
| | |||||
Other operating expense (income), net | | | | ( | |||||||||
Total operating expenses, net | | | | | |||||||||
Operating income |
| |
| |
| |
| | |||||
Interest income |
| |
| |
| |
| | |||||
Interest expense |
| ( |
| ( |
| ( |
| ( | |||||
Other income (expense), net | ( | — | ( | — | |||||||||
Income before income taxes |
| | | | | ||||||||
Income tax expense |
| |
| |
| |
| | |||||
Net income | $ | | $ | | $ | | $ | | |||||
Income per common share: | |||||||||||||
Basic | $ | | $ | | $ | | $ | | |||||
Diluted | $ | | $ | | $ | | $ | | |||||
Weighted average number of shares: | |||||||||||||
Basic |
| |
| |
| |
| | |||||
Diluted |
| |
| |
| |
| |
See accompanying Notes to the Consolidated Financial Statements.
4
Veeco Instruments Inc. and Subsidiaries
Consolidated Statements of Comprehensive Income
(in thousands)
(unaudited)
Three months ended June 30, | Six months ended June 30, | ||||||||||||
| 2025 |
| 2024 |
| 2025 |
| 2024 |
| |||||
Net income | $ | | $ | | $ | | $ | | |||||
Other comprehensive income (loss), net of tax: | |||||||||||||
Unrealized gain (loss) on available-for-sale securities |
| ( |
| ( |
| |
| ( | |||||
Change in currency translation adjustments |
| |
| ( |
| |
| ( | |||||
Total other comprehensive income (loss), net of tax |
| |
| ( |
| |
| ( | |||||
Total comprehensive income | $ | | $ | | $ | | $ | |
See accompanying Notes to the Consolidated Financial Statements.
5
Veeco Instruments Inc. and Subsidiaries
Consolidated Statements of Cash Flows
(in thousands)
(unaudited)
Six months ended June 30, | |||||||
| 2025 |
| 2024 |
| |||
Cash Flows from Operating Activities | |||||||
Net income | $ | | $ | | |||
Adjustments to reconcile net income to net cash provided by (used in) operating activities: | |||||||
Depreciation and amortization |
| |
| | |||
Non-cash interest expense | | | |||||
Deferred income taxes |
| |
| ( | |||
Share-based compensation expense |
| |
| | |||
Changes in contingent consideration | — | ( | |||||
Changes in operating assets and liabilities: | |||||||
Accounts receivable and contract assets |
| ( |
| ( | |||
Inventories |
| ( |
| ( | |||
Prepaid expenses and other current assets |
| |
| ( | |||
Accounts payable and accrued expenses |
| |
| | |||
Contract liabilities |
| ( |
| ( | |||
Income taxes receivable and payable, net |
| |
| — | |||
Other, net |
| ( |
| ( | |||
Net cash provided by (used in) operating activities |
| |
| | |||
Cash Flows from Investing Activities | |||||||
Capital expenditures |
| ( |
| ( | |||
Proceeds from the sale of investments |
| |
| | |||
Payments for purchases of investments |
| ( |
| ( | |||
Proceeds from sale of productive assets |
| — |
| | |||
Net cash provided by (used in) investing activities | | | |||||
Cash Flows from Financing Activities | |||||||
Restricted stock tax withholdings | ( | ( | |||||
Repayment of convertible debt | ( | — | |||||
Debt issuance costs | ( | — | |||||
Contingent consideration payments | — | ( | |||||
Proceeds (net of tax withholdings) from option exercises and employee stock purchase plan |
| |
| | |||
Net cash provided by (used in) financing activities |
| ( |
| ( | |||
Effect of exchange rate changes on cash and cash equivalents |
| |
| ( | |||
Net increase (decrease) in cash, cash equivalents, and restricted cash |
| |
| | |||
Cash, cash equivalents, and restricted cash - beginning of period |
| |
| | |||
Cash, cash equivalents, and restricted cash - end of period | $ | | $ | | |||
Supplemental Disclosure of Cash Flow Information | |||||||
Interest paid | $ | | $ | | |||
Net income taxes paid (refunded) | ( | | |||||
Non-cash activities | |||||||
Capital expenditures included in accounts payable and accrued expenses | | | |||||
Right-of-use assets obtained in exchange for lease obligations | | |
See accompanying Notes to the Consolidated Financial Statements.
6
Veeco Instruments Inc. and Subsidiaries
Notes to the Consolidated Financial Statements
(unaudited)
Note 1 — Basis of Presentation
The accompanying unaudited Consolidated Financial Statements of Veeco have been prepared in accordance with U.S. GAAP as defined in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification 270 for interim financial information and with the instructions to Rule 10-01 of Securities and Exchange Commission Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements as the interim information is an update of the information that was presented in Veeco’s most recent annual financial statements. For further information, refer to Veeco’s Consolidated Financial Statements and Notes thereto included in the Annual Report on Form 10-K for the year ended December 31, 2024 (“2024 Form 10-K”). In the opinion of management, all adjustments considered necessary for a fair presentation have been included. All such adjustments are of a normal, recurring nature.
Veeco reports interim quarters on a
The preparation of financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although these estimates are based on management’s knowledge of current events and actions it may undertake in the future, actual results may differ from these estimates.
Accounting Standards Recently Adopted
In December 2023, the FASB issued ASU 2023-09: Improvements to Income Tax Disclosures (Topic 740). This amendment requires public entities annually to disclose consistent categories and greater disaggregation of information in the rate reconciliation and for income taxes paid. It also includes certain other amendments to improve the effectiveness of annual income tax disclosures. This authoritative guidance is effective for the Company’s annual reporting periods beginning January 1, 2025. The amendments require increased annual disclosures on current and comparable reporting periods presented in annual company filings. The resulting new annual disclosure requirements will be reflected in the Company’s 2025 report on Form 10-K.
In November 2024, the FASB issued ASU 2024-04, Debt – Debt with Conversion and Other Options (Subtopic 470-20) which clarifies the conditions in which induced conversion accounting applies to convertible debt by outlining three criteria that must be met for an entity to apply the induced conversion model. The amendments in this ASU are effective for annual reporting periods beginning after December 15, 2025 (and interim reporting periods within those annual reporting periods), with early adoption permitted. The Company has decided to adopt ASU 2024-04 on a prospective basis effective during the three and six months ended June 30, 2025, and has applied the amendments in this ASU to the repurchase of the 2027 Notes. Refer to Note 4 Liabilities for further details.
Recent Accounting Standards Not Yet Adopted
In November 2024, the FASB issued ASU 2024-03, “Disaggregation of Income Statements Expenses (Subtopic 220-40),” to improve income statement expenses disclosure. The standard requires more detailed information related to the types of expenses, including (among other items) the amounts of purchases of inventory, employee compensation, depreciation and intangible asset amortization included within each interim and annual income statement’s expense caption, as applicable. This authoritative guidance can be applied prospectively or retrospectively and will be effective for financial statements issued for annual periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently in the process of evaluating the impact of adoption on its consolidated financial statements.
7
Veeco Instruments Inc. and Subsidiaries
Notes to the Consolidated Financial Statements - continued
(unaudited)
Note 2 — Income Per Common Share
Basic income per share is calculated by dividing net income by the weighted average number of shares outstanding during the period. Diluted income per share is calculated by dividing net income available to common shareholders by the weighted average number of shares used to calculate basic income per share plus the weighted average number of common share equivalents outstanding during the period. The dilutive effect of outstanding options to purchase common stock and share-based awards is considered in diluted income per share by application of the treasury stock method. The dilutive effect of performance share units is included in diluted income per common share if the performance targets have been achieved, or would have been achieved if the reporting date was the end of the contingency period. Finally, the Company includes the dilutive effect of shares issuable upon conversion of its Notes in the calculation of diluted income per share using the if-converted method. The Company must settle the principal amount of the 2029 Notes in cash, and has the option to settle any excess of the conversion value over the principal amount in any combination of cash or shares. As such, the Company only includes the excess shares that may be issuable above the principal amount of the 2029 Notes in the dilutive share count, if the effect would be dilutive.
The computations of basic and diluted income per share for the three and six months ended June 30, 2025 and 2024 are as follows:
Three months ended June 30, | Six months ended June 30, | ||||||||||||
| 2025 |
| 2024 |
| 2025 |
| 2024 |
| |||||
(in thousands, except per share amounts) | |||||||||||||
Numerator: | |||||||||||||
Net income | $ | | $ | | $ | | $ | | |||||
Interest expense associated with convertible notes | | | | | |||||||||
Net income available to common shareholders | $ | | $ | | $ | | $ | | |||||
Denominator: | |||||||||||||
Basic weighted average shares outstanding |
| |
| |
| |
| | |||||
Effect of potentially dilutive share-based awards | | | | | |||||||||
Dilutive effect of convertible notes |
| |
| |
| |
| | |||||
Diluted weighted average shares outstanding |
| |
| |
| |
| | |||||
Net income per common share: | |||||||||||||
Basic | $ | | $ | | $ | | $ | | |||||
Diluted | $ | | $ | | $ | | $ | | |||||
Potentially dilutive shares excluded from the diluted calculation as their effect would be antidilutive | | | | | |||||||||
Potential shares to be issued for settlement of the convertible notes excluded from the diluted calculation as their effect would be antidilutive | N/A | N/A | | N/A |
Note 3 — Assets
Investments
Short-term investments are generally classified as available-for-sale and reported at fair value, with unrealized gains and losses, net of tax, presented as a separate component of stockholders’ equity under the caption “Accumulated other comprehensive income” in the Consolidated Balance Sheets. These securities may include U.S. treasuries, government
8
Veeco Instruments Inc. and Subsidiaries
Notes to the Consolidated Financial Statements - continued
(unaudited)
agency securities, corporate debt, and commercial paper, all with maturities of greater than three months when purchased. All realized gains and losses and unrealized losses resulting from declines in fair value that are other than temporary are included in “Other operating expense (income), net” in the Consolidated Statements of Operations.
Fair value is the price that would be received for an asset or the amount paid to transfer a liability in an orderly transaction between market participants. Veeco classifies certain assets based on the following fair value hierarchy:
Level 1: Quoted prices in active markets that are unadjusted and accessible at the measurement date for identical, unrestricted assets or liabilities;
Level 2: Quoted prices for identical assets and liabilities in markets that are not active, quoted prices for similar assets and liabilities in active markets or financial instruments for which significant inputs are observable, either directly or indirectly; and
Level 3: Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.
A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Veeco has evaluated the estimated fair value of financial instruments using available market information and valuations as provided by third-party sources. The use of different market assumptions or estimation methodologies could have a significant effect on the estimated fair value amounts.
9
Veeco Instruments Inc. and Subsidiaries
Notes to the Consolidated Financial Statements - continued
(unaudited)
The following table presents the portion of Veeco’s assets that were measured at fair value on a recurring basis at June 30, 2025 and December 31, 2024:
| Level 1 |
| Level 2 |
| Level 3 |
| Total | |||||
(in thousands) | ||||||||||||
June 30, 2025 | ||||||||||||
Cash equivalents | ||||||||||||
Certificate of deposits and time deposits | $ | | $ | — | $ | — | $ | | ||||
Commercial paper | — | | — | | ||||||||
Money market cash | | — | — | | ||||||||
Total | $ | | $ | | $ | — | $ | | ||||
Short-term investments | ||||||||||||
U.S. treasuries | $ | | $ | — | $ | — | $ | | ||||
Government agency securities | — | | — | | ||||||||
Corporate debt | — | | — | | ||||||||
Total | $ | | $ | | $ | — | $ | | ||||
December 31, 2024 | ||||||||||||
Cash equivalents | ||||||||||||
Certificate of deposits and time deposits | $ | | $ | — | $ | — | $ | | ||||
Money market cash | | — | — | | ||||||||
Total | $ | | $ | — | $ | — | $ | | ||||
Short-term investments | ||||||||||||
U.S. treasuries | $ | | $ | — | $ | — | $ | | ||||
Government agency securities | — | | — | | ||||||||
Corporate debt | — | | — | | ||||||||
Commercial paper | — | | — | | ||||||||
Total | $ | | $ | | $ | — | $ | |
There were
At June 30, 2025 and December 31, 2024, the amortized cost and fair value of available-for-sale securities consist of:
|
| Gross |
| Gross |
| |||||||
Amortized | Unrealized | Unrealized | Estimated | |||||||||
Cost | Gains | Losses | Fair Value | |||||||||
(in thousands) | ||||||||||||
June 30, 2025 | ||||||||||||
U.S. treasuries | $ | | $ | | $ | ( | $ | | ||||
Government agency securities | | | ( | | ||||||||
Corporate debt | | | ( | | ||||||||
Total | $ | | $ | | $ | ( | $ | | ||||
December 31, 2024 | ||||||||||||
U.S. treasuries | $ | | $ | | $ | ( | $ | | ||||
Government agency securities | | | ( | | ||||||||
Corporate debt |
| | | ( |
| | ||||||
Commercial paper | | — | — | | ||||||||
Total | $ | | $ | | $ | ( | $ | |
10
Veeco Instruments Inc. and Subsidiaries
Notes to the Consolidated Financial Statements - continued
(unaudited)
Available-for-sale securities in a loss position at June 30, 2025 and December 31, 2024 consist of:
Continuous Loss Position | Continuous Loss Position | |||||||||||
for Less than 12 Months | for 12 Months or More | |||||||||||
|
| Gross |
|
| Gross | |||||||
Estimated | Unrealized | Estimated | Unrealized | |||||||||
Fair Value | Losses | Fair Value | Losses | |||||||||
(in thousands) | ||||||||||||
June 30, 2025 | ||||||||||||
U.S. treasuries | $ | | $ | ( | $ | — | $ | — | ||||
Government agency securities | | ( | — | — | ||||||||
Corporate debt |
| |
| ( |
| — |
| — | ||||
Total | $ | | $ | ( | $ | — | $ | — | ||||
December 31, 2024 | ||||||||||||
U.S. treasuries | $ | | $ | ( | $ | — | $ | — | ||||
Government agency securities | | ( | — | — | ||||||||
Corporate debt |
| |
| ( |
| — |
| — | ||||
Total | $ | | $ | ( | $ | — | $ | — |
The contractual maturities of securities classified as available-for-sale at June 30, 2025 were as follows:
June 30, 2025 | ||||||
Amortized | Estimated | |||||
Cost | Fair Value | |||||
(in thousands) | ||||||
Due in one year or less | $ | | $ | | ||
Due after one year through two years | |
| | |||
Total | $ | | $ | |
Actual maturities may differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without call or prepayment penalties. There were
Accounts Receivable
Accounts receivable is presented net of an allowance for doubtful accounts of $
11
Veeco Instruments Inc. and Subsidiaries
Notes to the Consolidated Financial Statements - continued
(unaudited)
Inventories
Inventories at June 30, 2025 and December 31, 2024 consist of the following:
June 30, | December 31, | |||||
| 2025 |
| 2024 | |||
(in thousands) | ||||||
Materials | $ | | $ | | ||
Work-in-process |
| |
| | ||
Finished goods |
| |
| | ||
Evaluation inventory | | | ||||
Total | $ | | $ | |
Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets primarily consist of supplier deposits, prepaid value-added tax, lease deposits, prepaid insurance, prepaid software and maintenance, and other receivables. The Company had deposits with its suppliers of $
Property, Plant, and Equipment
Property, plant, and equipment at June 30, 2025 and December 31, 2024 consist of the following:
June 30, | December 31, | |||||
| 2025 |
| 2024 | |||
(in thousands) | ||||||
Land | $ | | $ | | ||
Building and improvements |
| |
| | ||
Machinery and equipment (1) |
| |
| | ||
Leasehold improvements |
| |
| | ||
Gross property, plant, and equipment |
| |
| | ||
Less: accumulated depreciation and amortization |
| |
| | ||
Property, plant, and equipment, net | $ | | $ | |
(1) | Machinery and equipment also includes software, furniture and fixtures |
For the three and six months ended June 30, 2025, depreciation expense was $
Goodwill
Goodwill represents the future economic benefits arising from assets acquired in a business combination that are not individually identified and separately recognized. There were
Intangible Assets
Intangible assets consist of purchased technology, customer relationships, patents, trademarks and tradenames, licenses, and backlog, and are initially recorded at fair value. Long-lived intangible assets are amortized over their estimated useful lives in a method reflecting the pattern in which the economic benefits are consumed or amortized on a straight-line basis if such pattern cannot be reliably determined.
12
Veeco Instruments Inc. and Subsidiaries
Notes to the Consolidated Financial Statements - continued
(unaudited)
The components of purchased intangible assets were as follows:
June 30, 2025 | December 31, 2024 | |||||||||||||||||
Accumulated | Accumulated | |||||||||||||||||
| Gross |
| Amortization |
|
| Gross |
| Amortization |
| |||||||||
Carrying | and | Net | Carrying | and | Net | |||||||||||||
Amount | Impairment | Amount | Amount | Impairment | Amount | |||||||||||||
(in thousands) | ||||||||||||||||||
Technology | $ | | $ | | $ | | $ | | $ | | $ | | ||||||
Customer relationships | | | | | | | ||||||||||||
Trademarks and tradenames | | | — | | | — | ||||||||||||
Other |
| |
| |
| — |
| |
| |
| — | ||||||
Total | $ | | $ | | $ | | $ | | $ | | $ | |
Other intangible assets primarily consist of patents, licenses, and backlog.
Note 4 — Liabilities
Accrued Expenses and Other Current Liabilities
The components of accrued expenses and other current liabilities at June 30, 2025 and December 31, 2024 consist of:
June 30, | December 31, | |||||
| 2025 |
| 2024 | |||
(in thousands) | ||||||
Payroll and related benefits | $ | | $ | | ||
Warranty | | | ||||
Operating lease liabilities | | | ||||
Interest | | | ||||
Professional fees | | | ||||
Sales, use, and other taxes |
| |
| | ||
Contingent consideration | | | ||||
Other |
| |
| | ||
Total | $ | | $ | |
Warranty
Warranties are typically valid for
(in thousands) | |||
Balance - December 31, 2024 | $ | | |
Warranties issued |
| | |
Consumption of reserves |
| ( | |
Changes in estimate |
| ( | |
Balance - June 30, 2025 | $ | |
13
Veeco Instruments Inc. and Subsidiaries
Notes to the Consolidated Financial Statements - continued
(unaudited)
Contract Liabilities and Performance Obligations
Contract liabilities consist of unsatisfied performance obligations related to advanced payments received and billing in excess of revenue recognized. The contract liability balance as of December 31, 2024 was approximately $
This reduction in contract liabilities was offset in part by new billings for products and services which were unsatisfied performance obligations to customers and revenue had not yet been recognized as of June 30, 2025.
As of June 30, 2025, the Company has approximately $
Convertible Senior Notes
2025 Notes
On November 17, 2020, as part of the privately negotiated exchange agreement, the Company issued $
2027 Notes
On May 18, 2020, the Company completed a private offering of $
14
Veeco Instruments Inc. and Subsidiaries
Notes to the Consolidated Financial Statements - continued
(unaudited)
Statement of Operations, and a decrease to additional paid-in capital of $
2029 Notes
On May 19, 2023, the Company completed a private offering of $
The 2029 Notes are unsecured senior obligations of Veeco and rank senior in right of payment to any of Veeco’s subordinated indebtedness; equal in right of payment to all of Veeco’s unsecured indebtedness that is not subordinated; effectively subordinated in right of payment to any of Veeco’s secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally subordinated to all indebtedness and other liabilities (including trade payables) of Veeco’s subsidiaries.
The Company may redeem for cash, at its option, all or any portion of the outstanding 2029 Notes at any time on or after June 8, 2026, at a redemption price equal to
The 2029 Notes are convertible at the option of the holders upon the satisfaction of specified conditions and during certain periods as described below. The initial conversion rate is
Holders may convert all or any portion of their 2029 Notes, in multiples of
(i) | During any calendar quarter (and only during such calendar quarter), if the last reported sale price of the common stock for at least |
(ii) | During the |
15
Veeco Instruments Inc. and Subsidiaries
Notes to the Consolidated Financial Statements - continued
(unaudited)
(iii) | If the Company calls any or all of applicable series of the 2029 Notes for redemption at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or |
(iv) | Upon the occurrence of specified corporate events. |
Holders may convert their 2029 Notes at any time, regardless of the foregoing circumstances, on February 1, 2029, until the close of business on the business day immediately preceding the maturity date.
The 2025, 2027, and 2029 Notes were recorded as a single unit within liabilities in the consolidated balance sheets as the conversion features within the Notes were not derivatives that require bifurcation and the Notes did not involve a substantial premium. Transaction costs of $
The carrying value of the 2025 Notes, 2027 Notes, and 2029 Notes are as follows:
June 30, 2025 | December 31, 2024 | |||||||||||||||||
| Principal Amount |
| Unamortized |
| Net carrying value |
| Principal Amount |
| Unamortized |
| Net carrying value | |||||||
(in thousands) | ||||||||||||||||||
2025 Notes | $ | — | $ | — | $ | — | $ | | $ | ( | $ | | ||||||
2027 Notes | — | — | — | | ( | | ||||||||||||
2029 Notes | | ( | | | ( | | ||||||||||||
Net carrying value | $ | | $ | ( | $ | | $ | | $ | ( | $ | |
Total interest expense related to the 2025 Notes, 2027 Notes, and 2029 Notes is as follows:
Three months ended June 30, | Six months ended June 30, | ||||||||||||
| 2025 |
| 2024 |
| 2025 |
| 2024 | ||||||
| (in thousands) | ||||||||||||
Cash Interest Expense |
|
|
|
|
| ||||||||
Coupon interest expense - 2025 Notes | $ | — | $ | | $ | | $ | | |||||
Coupon interest expense - 2027 Notes | | | | | |||||||||
Coupon interest expense - 2029 Notes | | | | | |||||||||
Non-cash Interest Expense |
|
|
|
|
|
| |||||||
Amortization of debt discount/transaction costs- 2025 Notes | — | | | | |||||||||
Amortization of debt discount/transaction costs- 2027 Notes | | | | | |||||||||
Amortization of debt discount/transaction costs- 2029 Notes | | | | | |||||||||
Total Interest Expense | $ | | $ | | $ | | $ | |
The Company determined the
Capped Call Transactions
In connection with the offering of the 2027 Notes, on May 13, 2020, the Company entered into privately negotiated capped call transactions (the “Capped Call Transactions”), pursuant to capped call confirmations, covering the initial underlying shares of the 2027 Notes of approximately
16
Veeco Instruments Inc. and Subsidiaries
Notes to the Consolidated Financial Statements - continued
(unaudited)
The Capped Call Transactions feature a $
The Capped Call Transactions are separate transactions entered into by the Company with the capped call counterparties, are not part of the terms of the 2027 Notes and did not change the previous holders’ rights under the 2027 Notes. Previous holders of the 2027 Notes did not have any rights with respect to the Capped Call Transactions. The cost of the Capped Call Transactions is not expected to be tax-deductible as the Company did not elect to integrate the Capped Call Transactions into the 2027 Notes for tax purposes. The Company used a portion of the net proceeds from the offering of the 2027 Notes to pay for the Capped Call Transactions, and the cost of the Capped Call Transactions was recorded as a reduction of the Company’s additional paid-in capital in the accompanying consolidated financial statements.
Revolving Credit Facility
On December 16, 2021, the Company entered into a Loan and Security Agreement (the “Loan and Security Agreement, as amended”) providing for a senior secured revolving credit facility in an aggregate principal amount of $
Borrowings will bear interest at a floating rate which can be, at the Company’s option based on certain conditions in the Loan and Security Agreement, either (a) an alternate base rate plus an applicable rate ranging from
The Loan and Security Agreement, contains customary affirmative covenants for transactions of this type, including, among others, the provision of financial and other information to the administrative agent, notice to the administrative agent upon the occurrence of certain material events, preservation of existence, maintenance of properties and insurance, compliance with laws, including environmental laws, the provision of additional guarantees, and an affiliate transactions covenant, subject to certain exceptions. The Loan and Security Agreement, contains customary negative covenants, including, among others, restrictions on the ability to merge and consolidate with other companies, incur indebtedness, refinance our existing convertible notes, grant liens or security interests on assets, make investments, acquisitions, loans, or advances, pay dividends, and sell or otherwise transfer assets.
The Loan and Security Agreement, contains financial maintenance covenants that require the Borrower to maintain an Interest Coverage Ratio (as defined in the Loan and Security Agreement) of not less than
17
Veeco Instruments Inc. and Subsidiaries
Notes to the Consolidated Financial Statements - continued
(unaudited)
Leverage Ratio (as defined in the Loan and Security Agreement) of not more than
Other Liabilities
Other Liabilities at June 30, 2025 and December 31, 2024 was approximately $
Note 5 — Commitments and Contingencies
Leases
The Company’s operating leases primarily include real estate leases for properties used for manufacturing, R&D activities, sales and service, and administration, as well as certain equipment leases. Some leases may include options to renew for a period of up to
The following table provides the maturities of lease liabilities at June 30, 2025:
Operating | |||
| Leases | ||
(in thousands) | |||
Payments due by period: | |||
2025 | $ | | |
2026 | | ||
2027 | | ||
2028 | | ||
2029 | | ||
Thereafter | | ||
Total future minimum lease payments | | ||
Less: Imputed interest | ( | ||
Total | $ | | |
Reported as of June 30, 2025 | |||
$ | | ||
Long-term operating lease liabilities | | ||
$ | |
Operating lease costs for the three and six months ended June 30, 2025 were $
18
Veeco Instruments Inc. and Subsidiaries
Notes to the Consolidated Financial Statements - continued
(unaudited)
Cash outflows from operating leases for the six months ended June 30, 2025 and 2024 were $
Receivable Purchase Agreement
The Company entered into a receivable purchase agreement with a financial institution to sell certain of its trade receivables from customers without recourse, up to $
Purchase Commitments
Veeco has purchase commitments of $
Bank Guarantees
Veeco has bank guarantees and letters of credit issued by a financial institution on its behalf as needed. At June 30, 2025, outstanding bank guarantees and standby letters of credit totaled $
Legal Proceedings
The Company is involved in various legal proceedings arising in the normal course of business. The Company does not believe that the ultimate resolution of these matters will have a material adverse effect on its consolidated financial position, results of operations, or cash flows.
19
Veeco Instruments Inc. and Subsidiaries
Notes to the Consolidated Financial Statements - continued
(unaudited)
Note 6 — Equity
Statement of Stockholders’ Equity
The following tables present the changes in Stockholders’ Equity:
|
|
|
|
| Accumulated |
| |||||||||||
Additional | Other | ||||||||||||||||
Common Stock | Paid-in | Accumulated | Comprehensive | ||||||||||||||
Shares | Amount | Capital | Deficit | Income | Total | ||||||||||||
(in thousands) | |||||||||||||||||
Balance at December 31, 2024 |
| | $ | | $ | | $ | ( | $ | | $ | | |||||
Net income |
| — |
| — |
| — |
| |
| — |
| | |||||
Other comprehensive income (loss), net of tax |
| — |
| — |
| — |
| — |
| |
| | |||||
Share-based compensation expense |
| — |
| — |
| |
| — |
| — |
| | |||||
Settlement of the 2025 Notes | | | | — | — | | |||||||||||
Net issuance under employee stock plans | | | ( | — | — | ( | |||||||||||
Balance at March 31, 2025 |
| | $ | | $ | | $ | ( | $ | | $ | | |||||
Net income |
| — |
| — |
| — |
| |
| — |
| | |||||
Other comprehensive income (loss), net of tax |
| — |
| — |
| — |
| — |
| |
| | |||||
Share-based compensation expense |
| — |
| — |
| |
| — |
| — |
| | |||||
Settlement of the 2027 Notes | | | | — | — | | |||||||||||
Net issuance under employee stock plans |
| | | | — | — | | ||||||||||
Balance at June 30, 2025 |
| | $ | | $ | | $ | ( | $ | | $ | |
|
|
|
|
| Accumulated |
| |||||||||||
Additional | Other | ||||||||||||||||
Common Stock | Paid-in | Accumulated | Comprehensive | ||||||||||||||
Shares | Amount | Capital | Deficit | Income | Total | ||||||||||||
(in thousands) | |||||||||||||||||
Balance at December 31, 2023 |
| | $ | | $ | | $ | ( | $ | | $ | | |||||
Net income |
| — |
| — |
| — |
| |
| — |
| | |||||
Other comprehensive income (loss), net of tax |
| — |
| — |
| — |
| — |
| ( |
| ( | |||||
Share-based compensation expense |
| — |
| — |
| |
| — |
| — |
| | |||||
Net issuance under employee stock plans | | | ( | — |
| — | ( | ||||||||||
Balance at March 31, 2024 |
| | $ | | $ | | $ | ( | $ | | $ | | |||||
Net income (loss) |
| — |
| — |
| — |
| |
| — |
| | |||||
Other comprehensive income (loss), net of tax |
| — |
| — |
| — |
| — |
| ( |
| ( | |||||
Share-based compensation expense |
| — |
| — |
| |
| — |
| — |
| | |||||
Net issuance under employee stock plans | | | | — | — | | |||||||||||
Balance at June 30, 2024 |
| | $ | | $ | | $ | ( | $ | | $ | |
20
Veeco Instruments Inc. and Subsidiaries
Notes to the Consolidated Financial Statements - continued
(unaudited)
Accumulated Other Comprehensive Income (“AOCI”)
The following table presents the changes in the balances of each component of AOCI, net of tax:
Unrealized | |||||||||
Gains (Losses) | |||||||||
Foreign | on Available- | ||||||||
Currency | for-Sale | ||||||||
| Translation |
| Securities |
| Total | ||||
(in thousands) | |||||||||
Balance - December 31, 2024 | $ | | $ | ( | $ | | |||
Other comprehensive income (loss) |
| |
| |
| | |||
Balance - June 30, 2025 | $ | | $ | ( | $ | |
There were immaterial reclassifications from AOCI into net income for the three and six months ended June 30, 2025 and 2024.
Note 7 — Share-based Compensation
Restricted share awards are issued to employees and to members of our board of directors that are subject to specified restrictions and a risk of forfeiture. The restrictions typically lapse over
Share-based compensation expense was recognized in the following line items in the Consolidated Statements of Operations for the three and six months ended June 30, 2025 and 2024:
Three months ended June 30, | Six months ended June 30, | ||||||||||||
| 2025 |
| 2024 |
| 2025 |
| 2024 |
| |||||
(in thousands) | |||||||||||||
Cost of sales |
| $ | |
| $ | |
| $ | |
| $ | |
|
Research and development | | | | | |||||||||
Selling, general, and administrative | | | | | |||||||||
Total | $ | | $ | | $ | | $ | |
For the six months ended June 30, 2025, equity activity related to non-vested restricted shares and performance shares was as follows:
|
| Weighted | |||
Average | |||||
Number of | Grant Date | ||||
Shares | Fair Value | ||||
(in thousands) | |||||
Balance - December 31, 2024 | | $ | | ||
Granted | | | |||
Performance award adjustments | ( | | |||
Vested | ( | | |||
Forfeited | ( | | |||
Balance - June 30, 2025 | | $ | |
21
Veeco Instruments Inc. and Subsidiaries
Notes to the Consolidated Financial Statements - continued
(unaudited)
Note 8 — Income Taxes
Income taxes are estimated for each of the jurisdictions in which the Company operates. Deferred income taxes reflect the net tax effect of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, as well as the tax effect of carryforwards. Realization of net deferred tax assets is dependent on future taxable income.
At the end of each interim reporting period, the effective tax rate is aligned with expectations for the full year. This estimate is used to determine the income tax provision on a year-to-date basis and may change in subsequent interim periods.
Income before income taxes and income tax expense for the three and six months ended June 30, 2025 and 2024 were as follows:
Three months ended June 30, | Six months ended June 30, |
| |||||||||||
| 2025 |
| 2024 |
| 2025 |
| 2024 |
| |||||
(in thousands, except percentages) |
| ||||||||||||
Income before income taxes | $ | | $ | | $ | | $ | | |||||
Income tax expense |
| $ | |
| $ | | $ | | $ | | |||
Effective tax rate |
|
|
|
The Company’s income tax expense for the three and six months ended June 30, 2025 was $
For the three and six months ended June 30, 2025, the effective tax rate was favorably impacted by the tax benefits related to Foreign-Derived Intangible Income and research and development tax credits. Additionally, the effective tax rate was also impacted by a discrete income tax expense resulting from the share-based compensation shortfall. For the three and six months ended June 30, 2024, the effective tax rate was favorably impacted by the tax benefits related to Foreign-Derived Intangible Income and research and development tax credits. Additionally, the effective tax rate was also lower than the U.S. statutory tax rate primarily relating to a discrete income tax benefit for share-based compensation windfall.
Subsequent Event
The One Big Beautiful Bill Act (“OBBBA”) was enacted on July 4, 2025, which contains a broad range of tax law changes affecting businesses. The provisions of the OBBBA have different effective dates where some are effective in 2025 and others not until 2026. The Company continues to evaluate the full effects of the legislation. Based on our preliminary analysis, the OBBBA is not currently expected to materially impact the Company’s financial position, results of operations or cash flows in the current fiscal year. As the legislation was signed into law after the close of our second quarter, the impacts are not included in the Company’s consolidated operating results for the three and six months ended June 30, 2025.
Note 9 — Segment Reporting and Geographic Information
The Company operates and measures its results in
22
Veeco Instruments Inc. and Subsidiaries
Notes to the Consolidated Financial Statements - continued
(unaudited)
The Company does not have intra-entity sales or transfers. The CODM uses net income to evaluate income generated from segment assets (return on assets) in deciding whether to reinvest profits into the segment or into other parts of the Company, such as for acquisitions. Net income is used to monitor forecast versus actual results. The CODM also uses net income in competitive analysis by benchmarking the Company’s competitors. The competitive analysis along with the monitoring of forecasted versus actual results are used in assessing performance of the segment. The Company regularly provides management reports to the CODM on a consolidated expense basis which includes actuals, forecasted, and budgeted information. These reports are similar to the Company’s consolidated financial statements.
There are no additional expenses categories and amounts that meet the definition of significant expense items that are regularly provided to the CODM and included in the reported measure of net income.
Veeco serves the following
Semiconductor
The Semiconductor market refers to early process steps in logic and memory applications where silicon wafers are processed. There are many different process steps in forming patterned wafers, such as deposition, etching, masking, and doping, where the microchips are created but remain on the silicon wafer. This market includes mask blank production for extreme ultraviolet (“EUV”) lithography, as well as Advanced Packaging, which refers to a portfolio of wafer-level assembly technologies that enable improved performance of electronic products, such as smartphones, high-end servers, and graphical processors.
Compound Semiconductor
The Compound Semiconductor market includes Photonics, Power Electronics, RF Filters and Amplifiers, and Solar applications. Photonics refers to light source technologies and laser-based solutions for 3D sensing, datacom and telecom applications. This includes micro-LED, laser diodes, edge emitting lasers and vertical cavity surface emitting lasers (“VCSELs”). Power Electronics refers to semiconductor devices such as rectifiers, inverters and converters for the control and conversion of electric power in applications such as fast or wireless charging of consumer electronics and automotive applications. RF power amplifiers and filters (including surface acoustic wave (“SAW”) and bulk acoustic wave (“BAW”) filters) are used in 5G communications infrastructure, smartphones, tablets, and mobile devices. They make use of radio waves for wireless broadcasting and/or communications. Solar refers to power obtained by harnessing the energy of the sun through the use of compound semiconductor devices such as photovoltaics.
Data Storage
Data Storage refers to the Hard Disk Drive (“HDD”) market, for which our systems enable customers to manufacture thin film magnetic heads for hard disk drives as part of large capacity storage applications.
Scientific & Other
Scientific & Other refers to advanced materials research and a range of manufacturing applications including optical coatings (laser mirrors, optical filters, and anti-reflective coatings).
23
Veeco Instruments Inc. and Subsidiaries
Notes to the Consolidated Financial Statements - continued
(unaudited)
Sales by end-market and geographic region for the three and six months ended June 30, 2025 and 2024 were as follows:
Three months ended June 30, | Six months ended June 30, | ||||||||||||
| 2025 | 2024 |
| 2025 | 2024 |
| |||||||
(in thousands) | |||||||||||||
Sales by end-market | |||||||||||||
Semiconductor | $ | | $ | | $ | | $ | | |||||
Compound Semiconductor | | | | | |||||||||
Data Storage |
| |
| |
| |
| | |||||
Scientific & Other |
| |
| |
| |
| | |||||
Total | $ | | $ | | $ | | $ | | |||||
Sales by geographic region | |||||||||||||
United States | $ | | $ | | $ | | $ | | |||||
EMEA(1) | | | | | |||||||||
China | | | | | |||||||||
Rest of APAC | | | | | |||||||||
Rest of World |
| |
| |
| |
| | |||||
Total | $ | | $ | | $ | | $ | |
(1) | EMEA consists of Europe, the Middle East, and Africa |
For geographic reporting, sales are attributed to the location in which the customer facility is located.
24
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Cautionary Statement Regarding Forward Looking Statements
Management’s Discussion and Analysis of Financial Condition and Results of Operations (MD&A) is intended to facilitate an understanding of our business and results of operations. This MD&A should be read in conjunction with our Consolidated Financial Statements and the accompanying Notes to Consolidated Financial Statements included elsewhere in this Form 10-Q. The following discussion contains forward-looking statements and should also be read in conjunction with the cautionary statement set forth at the beginning of this Form 10-Q.
The following section generally discusses 2025 and 2024 items and year-to-year comparisons between 2025 and 2024. Discussions of 2024 items that are not included in this Form 10-Q can be found in "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Item 2 of our Quarterly Report on Form 10-Q for the interim period ended June 30, 2024, filed on August 6, 2024.
Executive Summary
We are an innovative manufacturer of semiconductor process equipment. Our proven ion beam, laser annealing, lithography, MOCVD, and single wafer wet processing technologies play an integral role in the fabrication and packaging of advanced semiconductor devices. With equipment designed to optimize performance, yield and cost of ownership, Veeco holds leading technology positions in the markets we serve. To learn more about Veeco’s systems and service offerings, visit www.veeco.com.
Business Update
The Semiconductor industry has historically demonstrated cyclicality based on fluctuations in global chip demand and production capacity. Sales in the Semiconductor industry are estimated to have increased year-over-year in 2024 to around $650 billion. Looking ahead, industry analysts are forecasting long-term growth of the industry, driven by secular growth trends such as artificial intelligence, high-performance computing, mobile connectivity, and the electrification of the automotive industry. Additionally, government investments in the Semiconductor industry are projected to accelerate global spending in next-generation technologies.
Growth in the Semiconductor industry, coupled with increasing technological complexity of Semiconductor chips, are expected to drive long-term growth in WFE spending. In an effort to improve chip performance, optimize power consumption, and reduce costs, today’s most advanced Semiconductor manufacturers are shrinking device geometries, investing in more complex transistor designs such as Gate-All-Around and exploring 3D architectures. As a result, growth of the WFE market is forecasted to keep pace with long-term growth of the Semiconductor industry, which we believe should benefit semiconductor capital equipment providers, including Veeco.
Our strategy of investing in advanced logic and memory has enabled our Semiconductor business to outperform WFE growth for four consecutive years. Veeco’s technologies are at the forefront of enabling new technical innovations in the manufacture of high-performance AI chips and High-Bandwidth Memory (“HBM”). We continue to invest in new technologies to expand our SAM to a broad range of new applications.
While the long-term outlook of the Semiconductor industry remains favorable, recently enacted tariffs, foreign and domestic, have resulted in uncertainty across Veeco’s business. The tariffs have resulted in an increase in certain of our costs and those of our customers and could impact future end market demand. Given the dynamic nature of the situation, we continue to evaluate the potential impacts to our business, and our team is working diligently with our suppliers and customers to assess, manage and mitigate the related impacts.
Semiconductor revenue increased by 13% in the second quarter from the comparable prior year period, comprising 75% of total revenue. Growth was primarily driven by an increase in system shipments of our Ion Beam Deposition LDD system for mask blanks and our Advanced Packaging wet processing systems.
25
Our laser annealing solutions continue to gain traction at advanced logic nodes, highlighted by recent order activity and shipments to leading-edge logic customers Gate-All-Around nodes. In the memory market, we continue to ship LSA systems to a Tier 1 customer for high volume production of HBM and advanced DRAM devices. While our growth strategy is predominately focused on advanced node logic and memory, LSA shipments to mature node customers increased in 2023 and 2024, predominantly driven by new greenfield fabs and capacity additions in China.
We have two next generation laser annealing systems under evaluation at Tier 1 foundry and logic customers. This next generation system, the NSA500, covers the nano-second annealing regime and complements our LSA product. This new system is part of our continued effort to enable our customers’ product roadmap by providing annealing solutions and driving higher device performance. Nanosecond annealing provides Veeco with an opportunity to expand our laser annealing SAM for new advanced node logic and memory applications, including low thermal budget anneals for Gate-All-Around transistors and advanced 3D devices.
The ongoing adoption of EUV Lithography for advanced node semiconductor manufacturing continues to drive demand for our Ion Beam Deposition LDD system for mask blanks. Leading logic and memory customers expect EUV and High Numerical Aperture (“High-NA”) lithography to be integral to their future roadmaps, which our Ion Beam Deposition technology is a key enabler of. Our product roadmap is well positioned as the industry adopts next-generation High-NA EUV lithography, and we are expanding our EUV related business to new mask blank applications.
We also have two Ion Beam Deposition “IBD300” systems under evaluation at leading DRAM memory customers. Our IBD300 system provides Veeco with another opportunity to expand our SAM to advanced node applications where low resistance films are critical. These initial systems are being evaluated for advanced memory applications, such as DRAM bitline.
In Advanced Packaging, our Wet Processing systems are used for several applications, and we continue to see strong demand driven by Heterogenous Integration and 3D Packaging for AI. In the fourth quarter of 2024, we announced over $50 million in orders for our Wet Processing systems from a leading foundry, a HBM manufacturer, and OSATs driven by AI and high-performance computing. In the first quarter of 2025, we announced that our wet processing systems were qualified by an IDM for two new applications, and the customer also placed initial orders for these applications. Both applications represent key Served Available Market expansion opportunities for our Wet Processing systems at separate Tier 1 customers.
Our Advanced Packaging lithography systems are used for packaging applications such as fan out wafer level packaging and other advanced packaging solutions. After two years of slow order activity driven by consumer markets, we’re seeing an increase in order activity from several customers.
Looking ahead, we anticipate seeing growth in leading-edge investment driven by new nodes and AI-related demand, including investment in Gate-All-Around nodes, High-Bandwidth Memory, and 3D packaging for AI. At the same time, engagement with customers in China has decreased quarter over quarter, and we expect a continued decline in China revenue for the second half of 2025.
Veeco also serves customers in the Compound Semiconductor, Data Storage, and Scientific & Other markets. We address the Compound Semiconductor market with a broad portfolio of technologies, including Wet Processing, MOCVD, MBE and Ion Beam, for Power Electronics, Photonics, and 5G RF applications. Sales in the Compound Semiconductor market declined in the second quarter from the comparable prior year period. In GaN Power, emerging use cases have driven some traditional silicon power electronics manufacturers to consider adoption of GaN at 300mm, and we have an evaluation system outstanding at a Tier 1 power device customer. We are also seeing photonics opportunities in areas such as solar driven by demand for low orbit satellites and MicroLEDs for applications such as luxury TVs, AR/VR, and automotive.
We address the Data Storage market with sales of our Ion Beam technology. Demand for our Ion Beam products is driven by demand for cloud-based storage. Revenue from our Data Storage declined in the second quarter from the comparable prior year period. Looking ahead, while customer utilizations are improving, they are not investing to
26
expand new system capacity in 2025. As a result, we expect an approximate $60 to $70 million reduction in revenue in our Data Storage business in 2025.
Sales in the Scientific & Other market are largely driven by sales to government-funded laboratories, universities, and research institutions. We address the Scientific & Other market with several technologies, including MBE, ALD, MOCVD, Wet Processing, and IBD/IBE, which support scientific, optical coating and other applications, and sales in this market increased in the second quarter from the comparable prior year period.
Results of Operations
For the three months ended June 30, 2025 and 2024
The following table presents revenue and expense line items reported in our Consolidated Statements of Operations for the indicated periods in 2025 and 2024 and the period-over-period dollar and percentage changes for those line items. Our results of operations are reported as one business segment, represented by our single operating segment.
Three Months Ended June 30, | Change | ||||||||||||||||||
2025 | 2024 | Period to Period | |||||||||||||||||
(dollars in thousands) | |||||||||||||||||||
Net sales |
| $ | 166,104 |
| 100% | $ | 175,879 |
| 100% | $ | (9,775) |
| (6)% |
| |||||
Cost of sales |
| 97,377 |
| 59% |
| 100,489 |
| 57% |
| (3,112) |
| (3)% | |||||||
Gross profit |
| 68,727 |
| 41% |
| 75,390 |
| 43% |
| (6,663) |
| (9)% | |||||||
Operating expenses, net: |
|
|
|
|
|
|
|
|
|
| |||||||||
Research and development |
| 31,560 |
| 19% |
| 31,696 |
| 18% |
| (136) |
| (0)% | |||||||
Selling, general, and administrative |
| 23,927 |
| 14% |
| 24,595 |
| 14% |
| (668) |
| (3)% | |||||||
Amortization of intangible assets |
| 821 |
| 0% |
| 1,825 |
| 1% |
| (1,004) |
| (55)% | |||||||
Other operating expense (income), net |
| 49 |
| 0% |
| 552 |
| - |
| (503) |
| (91)% | |||||||
Total operating expenses, net |
| 56,357 |
| 34% |
| 58,668 |
| 33% |
| (2,311) |
| (4)% | |||||||
Operating income |
| 12,370 |
| 7% |
| 16,722 |
| 10% |
| (4,352) |
| (26)% | |||||||
Interest income, net |
| 905 |
| 1% |
| 349 |
| 0% |
| 556 |
| 159% | |||||||
Other income (expense), net | (653) | (0)% | — | - |
| (653) |
| * | |||||||||||
Income before income taxes |
| 12,622 |
| 8% |
| 17,071 |
| 10% |
| (4,449) |
| (26)% | |||||||
Income tax expense |
| 889 |
| 1% |
| 2,127 |
| 1% |
| (1,238) |
| (58)% | |||||||
Net income | $ | 11,733 |
| 7% | $ | 14,944 |
| 8% | $ | (3,211) |
| (21)% |
* | Not meaningful |
27
Net Sales
The following is an analysis of sales by market and by region:
Three Months Ended June 30, | Change |
| |||||||||||||||||
2025 | 2024 | Period to Period |
| ||||||||||||||||
(dollars in thousands) |
| ||||||||||||||||||
Sales by end-market |
|
|
|
|
|
|
|
|
|
|
| ||||||||
Semiconductor | $ | 123,874 |
| 75% | $ | 109,936 |
| 63% | $ | 13,938 |
| 13% | |||||||
Compound Semiconductor |
| 14,197 |
| 9% |
| 18,223 |
| 10% |
| (4,026) |
| (22)% | |||||||
Data Storage |
| 12,354 |
| 7% |
| 33,960 |
| 19% |
| (21,606) |
| (64)% | |||||||
Scientific & Other |
| 15,679 |
| 9% |
| 13,760 |
| 8% |
| 1,919 |
| 14% | |||||||
Total | $ | 166,104 |
| 100% | $ | 175,879 |
| 100% | $ | (9,775) |
| (6)% | |||||||
Sales by geographic region |
|
|
|
|
|
|
|
|
|
|
| ||||||||
United States | $ | 21,852 |
| 13% | $ | 42,744 |
| 24% | $ | (20,892) |
| (49)% | |||||||
EMEA |
| 18,533 |
| 11% |
| 23,802 |
| 14% |
| (5,269) |
| (22)% | |||||||
China | 27,490 | 17% | 65,376 | 37% | (37,886) |
| (58)% | ||||||||||||
Rest of APAC |
| 98,186 |
| 59% |
| 43,935 |
| 25% |
| 54,251 |
| 123% | |||||||
Rest of World |
| 43 |
| - |
| 22 |
| - |
| 21 |
| 95% | |||||||
Total | $ | 166,104 |
| 100% | $ | 175,879 |
| 100% | $ | (9,775) |
| (6)% |
Sales decreased for the three months ended June 30, 2025 against the comparable prior year period driven by a decrease in sales in the Data Storage and Compound Semiconductor markets, partially offset by an increase in sales in the Semiconductor and Scientific & Other markets. By geography, sales decreased in the China, United States, and EMEA, partially offset by increased sales in the Rest of APAC region. Sales in the Rest of APAC region for the three months ended June 30, 2025 included sales in Taiwan, Singapore and Japan of $45.5 million, $23.4 million and $14.8 million respectively. Sales in the Rest of APAC region for the three months ended June 30, 2024 included sales in Taiwan and Japan of $21.0 million, and $8.8 million respectively. In light of the global nature of our business, we are impacted by conditions in the various countries in which we and our customers operate, including the recent tariff and trade dynamics. We expect there will continue to be year-to-year variations in our future sales distribution across markets and geographies.
Gross Profit
For the three months ended June 30, 2025, gross profit decreased against the comparable prior period primarily due to a decrease in sales volume, as well as a decrease in gross margins. Gross margins decreased principally due to lower volume and higher manufacturing costs partially offset by favorable product mix. Additionally other factors will cause our gross margins to fluctuate each period. We expect higher costs in future periods as we incur tariffs on imported materials from overseas suppliers, as well as higher costs from domestic suppliers incurring tariffs on their imports.
Research and Development
The markets we serve are characterized by continuous technological development and product innovation, and we invest in various research and development initiatives to maintain our competitive advantage and achieve our growth objectives. Research and development expenses remained consistent for the three months ended June 30, 2025 against the comparable prior period.
Selling, General, and Administrative
Selling, general, and administrative expenses remained consistent for the three months ended June 30, 2025 against the comparable prior period.
28
Amortization Expense
Amortization expense decreased compared to the comparable prior year period primarily due to changes in amortization expense to reflect expected cash flows of certain intangible assets, and certain other intangible assets becoming fully amortized, as well as the full impairment of the Epiluvac related intangibles in 2024.
Interest Income (Expense)
We recorded net interest income of $0.9 million for the three months ended June 30, 2025, compared to net interest income of $0.3 million for the comparable prior year period. The increase in net interest income was primarily due to reduced interest expense on the 2025 Notes as they matured on January 15, 2025 and the 2027 Notes that were settled on May 15, 2025.
Income Taxes
At the end of each interim reporting period, we estimate the effective income tax rate expected to be applicable for the full year. This estimate is used to determine the income tax provision or benefit on a year-to-date basis and may change in subsequent interim periods.
Our tax expense for the three months ended June 30, 2025, was $0.9 million, compared to $2.1 million of tax expense for the comparable prior period. For the three months ended June 30, 2025, the effective tax rate was lower than the U.S. statutory tax rate primarily relating to tax benefits related to Foreign-Derived Intangible Income and research and development tax credits. For the three months ended June 30, 2024, the effective tax rate was favorably impacted by the tax benefits related to Foreign-Derived Intangible Income and research and development tax credits. Additionally, the effective tax rate was also lower than the U.S. statutory tax rate primarily relating to a discrete income tax benefit for share-based compensation windfall.
29
For the six months ended June 30, 2025 and 2024
The following table presents revenue and expense line items reported in our Consolidated Statements of Operations for the indicated periods in 2025 and 2024 and the period-over-period dollar and percentage changes for those line items. Our results of operations are reported as one business segment, represented by our single operating segment.
Six Months Ended June 30, | Change | |||||||||||||||||
2025 | 2024 | Period to Period | ||||||||||||||||
(dollars in thousands) | ||||||||||||||||||
Net sales |
| $ | 333,396 |
| 100% | $ | 350,363 |
| 100% | $ | (16,967) |
| (5)% | |||||
Cost of sales |
| 196,202 |
| 59% |
| 199,554 |
| 57% |
| (3,352) |
| (2)% | ||||||
Gross profit |
| 137,194 |
| 41% |
| 150,809 |
| 43% |
| (13,615) |
| (9)% | ||||||
Operating expenses, net: |
|
|
|
|
|
|
|
|
|
| ||||||||
Research and development |
| 60,074 |
| 18% |
| 61,338 |
| 18% |
| (1,264) |
| (2)% | ||||||
Selling, general, and administrative |
| 48,955 |
| 15% |
| 49,295 |
| 14% |
| (340) |
| (1)% | ||||||
Amortization of intangible assets |
| 1,642 |
| 0% |
| 3,716 |
| 1% |
| (2,074) |
| (56)% | ||||||
Other operating expense (income), net |
| 5 |
| 0% |
| (2,307) |
| (1)% |
| 2,312 |
| * | ||||||
Total operating expenses, net |
| 110,676 |
| 33% |
| 112,042 |
| 32% |
| (1,366) |
| (1)% | ||||||
Operating income (loss) |
| 26,518 |
| 8% |
| 38,767 |
| 11% |
| (12,249) |
| (32)% | ||||||
Interest income (expense), net |
| 1,741 |
| 1% |
| 1,054 |
| 0% |
| 687 |
| 65% | ||||||
Other income (expense), net | (653) | (0)% | — | 0% | (653) | * | ||||||||||||
Income (loss) before income taxes |
| 27,606 |
| 8% |
| 39,821 |
| 11% |
| (12,215) |
| (31)% | ||||||
Income tax expense (benefit) |
| 3,926 |
| 1% |
| 3,023 |
| 1% |
| 903 |
| 30% | ||||||
Net income (loss) | $ | 23,680 |
| 7% | $ | 36,798 |
| 11% | $ | (13,118) |
| (36)% |
* | Not meaningful |
Net Sales
The following is an analysis of sales by market and by region:
Six Months Ended June 30, | Change | ||||||||||||||||
2025 | 2024 | Period to Period | |||||||||||||||
(dollars in thousands) | |||||||||||||||||
Sales by end-market |
|
|
|
|
|
|
|
|
|
| |||||||
Semiconductor | $ | 247,697 |
| 74% | $ | 230,320 |
| 66% | $ | 17,377 |
| 8% | |||||
Compound Semiconductor |
| 28,594 |
| 9% |
| 39,225 |
| 11% |
| (10,631) |
| (27)% | |||||
Data Storage |
| 19,059 |
| 6% |
| 51,977 |
| 15% |
| (32,918) |
| (63)% | |||||
Scientific & Other | 38,046 |
| 11% | 28,841 |
| 8% | 9,205 |
| 32% | ||||||||
Total | $ | 333,396 |
| 100% | $ | 350,363 |
| 100% | $ | (16,967) |
| (5)% | |||||
Sales by geographic region |
|
|
|
|
|
|
|
|
|
|
| ||||||
United States | $ | 45,914 |
| 14% | $ | 70,612 |
| 20% | $ | (24,698) |
| (35)% | |||||
EMEA |
| 30,870 |
| 9% |
| 32,290 |
| 9% |
| (1,420) |
| (4)% | |||||
China |
| 98,382 |
| 30% |
| 129,684 |
| 38% |
| (31,302) |
| (24)% | |||||
Rest of APAC |
| 158,162 |
| 47% |
| 117,155 |
| 33% |
| 41,007 |
| 35% | |||||
Rest of World | 68 | - | 622 | - | (554) | (89)% | |||||||||||
Total | $ | 333,396 |
| 100% | $ | 350,363 |
| 100% | $ | (16,967) |
| (5)% |
Sales decreased for the six months ended June 30, 2025 against the comparable prior year period driven by a decrease in sales in the Data Storage and Compound Semiconductor markets, partially offset by an increase in sales in the Semiconductor and Scientific & Other markets. By geography, sales decreased in the China, United States, EMEA, and the Rest of the World partially offset by increased sales in the Rest of APAC region. Sales in the Rest of APAC region
30
for the six months ended June 30, 2025 included sales in Taiwan, Singapore, and Japan of $78.0 million, $29.4 million, and $28.7 million, respectively. Sales in the Rest of APAC region for the six months ended June 30, 2024 included sales in Japan and Taiwan of $41.8 million, and $40.3 million respectively. In light of the global nature of our business, we are impacted by conditions in the various countries in which we and our customers operate, including the recent tariff and trade dynamics. We expect there will continue to be year-to-year variations in our future sales distribution across markets and geographies.
Gross Profit
For the six months ended June 30, 2025, gross profit decreased against the comparable prior period primarily due to a decrease in sales volume, as well as a decrease in gross margins. Gross margins decreased principally due to lower volume, unfavorable product mix and higher manufacturing costs. Additionally other factors will cause our gross margins to fluctuate each period. We expect higher costs in future periods as we incur tariffs on imported materials from overseas suppliers, as well as higher costs from domestic suppliers incurring tariffs on their imports.
Research and Development
The markets we serve are characterized by continuous technological development and product innovation, and we invest in various research and development initiatives to maintain our competitive advantage and achieve our growth objectives. Research and development expenses remained consistent for the six months ended June 30, 2025 against the comparable prior period.
Selling, General, and Administrative
Selling, general, and administrative expenses remained consistent for the six months ended June 30, 2025 against the comparable prior period.
Amortization Expense
Amortization expense decreased compared to the comparable prior year period primarily due to changes in amortization expense to reflect expected cash flows of certain intangible assets, and certain other intangible assets becoming fully amortized, as well as the full impairment of the Epiluvac related intangibles in 2024.
Interest Income (Expense)
We recorded net interest income of $1.7 million for the six months ended June 30, 2025, compared to net interest income of $1.1 million for the comparable prior year period. The increase in net interest income was primarily due to reduced interest expense on the 2025 Notes as they matured on January 15, 2025 and the 2027 Notes that were settled on May 15, 2025.
Income Taxes
At the end of each interim reporting period, we estimate the effective income tax rate expected to be applicable for the full year. This estimate is used to determine the income tax provision or benefit on a year-to-date basis and may change in subsequent interim periods.
Our tax expense for the six months ended June 30, 2025, was $3.9 million, compared to $3.0 million of tax expense for the comparable prior period. For the six months ended June 30, 2025, the effective tax rate was favorably impacted by tax benefits related to Foreign-Derived Intangible Income and research and development tax credits, partially offset by a discrete income tax expense resulting from the share-based compensation shortfall. For the six months ended June 30, 2024, the effective tax rate was favorably impacted by the tax benefits related to Foreign-Derived Intangible Income and research and development tax credits. Additionally, the effective tax rate was also lower than the U.S. statutory tax rate primarily relating to a discrete income tax benefit for share-based compensation windfall.
31
Liquidity and Capital Resources
Our cash and cash equivalents, restricted cash, and short-term investments are as follows:
June 30, | December 31, | |||||
| 2025 |
| 2024 | |||
(in thousands) | ||||||
Cash and cash equivalents | $ | 188,902 | $ | 145,595 | ||
Restricted cash |
| 87 |
| 224 | ||
Short-term investments |
| 165,890 |
| 198,719 | ||
Total | $ | 354,879 | $ | 344,538 |
At June 30, 2025 and December 31, 2024, cash and cash equivalents of $36.4 million and $45.1 million, respectively, were held outside the United States. As of June 30, 2025, we had $22.2 million of accumulated undistributed earnings generated by our non-U.S. subsidiaries for which the U.S. tax has previously been provided. Approximately $8.8 million of undistributed earnings will be subject to foreign withholding taxes if distributed back to the United States and we accrued $0.9 million for foreign withholding taxes for the undistributed earnings.
We believe that our projected cash flow from operations, combined with our cash and short-term investments, will be sufficient to meet our projected working capital requirements, contractual obligations, and other cash flow needs for the next twelve months, including scheduled principal and interest payments on our convertible senior notes, purchase commitments, and payments required under our operating leases.
A summary of the cash flow activity for the six months ended June 30, 2025 and 2024 is as follows:
Cash Flows from Operating Activities
Six Months Ended June 30, |
| ||||||
| 2025 |
| 2024 |
| |||
(in thousands) | |||||||
Net income | $ | 23,680 | $ | 36,798 | |||
Non-cash items: | |||||||
Depreciation and amortization |
| 10,136 |
| 13,008 | |||
Non-cash interest expense |
| 550 |
| 613 | |||
Deferred income taxes |
| 667 |
| (67) | |||
Share-based compensation expense |
| 18,859 |
| 17,315 | |||
Change in contingent consideration |
| — |
| (131) | |||
Changes in operating assets and liabilities |
| (24,858) |
| (49,720) | |||
Net cash provided by (used in) operating activities | $ | 29,034 | $ | 17,816 |
Net cash provided by operating activities was $29.0 million for the six months ended June 30, 2025 and was due to net income of $23.7 million and adjustments for non-cash items of $30.2 million, partially offset by a decrease in cash flow from changes in operating assets and liabilities of $24.9 million. The changes in operating assets and liabilities were largely attributable to a decrease in contract liabilities and increases in accounts receivables, and inventories, partially offset by a decrease in prepaid expenses and accrued expenses.
32
Cash Flows from Investing Activities
Six Months Ended June 30, | |||||||
| 2025 |
| 2024 |
| |||
(in thousands) | |||||||
Capital expenditures | $ | (10,350) | $ | (8,943) | |||
Changes in investments, net |
| 34,408 |
| 17,691 | |||
Proceeds from the sale of productive assets | — | 2,033 | |||||
Net cash provided by (used in) investing activities | $ | 24,058 | $ | 10,781 |
The cash provided by investing activities during the six months ended June 30, 2025 was primarily attributable to net cash provided for investment activity, partially offset by capital expenditures. The cash provided by investing activities during the six months ended June 30, 2024 was primarily attributable to net cash provided by net investment activity and proceeds from the sale of productive assets, partially offset by capital expenditures.
Cash Flows from Financing Activities
Six Months Ended June 30, | |||||||
| 2025 |
| 2024 |
| |||
(in thousands) | |||||||
Settlement of equity awards, net of withholding taxes | $ | (3,868) | $ | (11,402) | |||
Debt issuance costs | (885) | — | |||||
Repayment of convertible debt | (5,229) | — | |||||
Contingent consideration payment | — | (1,818) | |||||
Net cash provided by (used in) financing activities | $ | (9,982) | $ | (13,220) |
The cash used in financing activities for the six months ended June 30, 2025 was related to cash used to settle taxes related to employee equity programs, settlement of the 2027 Notes, and debt issuance costs associated with the execution of the Fourth Amendment of the Loan and Security Agreement, partially offset by cash received under the Employee Stock Purchase Plan. The cash used in financing activities for the six months ended June 30, 2024 was related to cash used to settle taxes related to employee equity programs and contingent consideration payment related to Epiluvac acquisition, partially offset by cash received under the Employee Stock Purchase Plan.
Convertible Senior Notes
We have $230.0 million outstanding principal balance of 2.875% convertible senior notes that bear interest at a rate of 2.875% per year, payable semiannually in arrears on June 1 and December 1 of each year, and mature on June 1, 2029, unless earlier purchased by the Company, redeemed, or converted.
We believe that we have sufficient capital resources and cash flows from operations to support scheduled interest payments on this debt. In addition, in June 2025, we increased the total funds available to us through our revolving credit facility from $225 million to $250 million and extended the maturity until June 16, 2030, subject to a springing maturity date of March 2, 2029. The Company has no immediate plans to draw down on the facility. Interest under the facility is variable based on the Company’s secured net leverage ratio and is expected to bear interest based on SOFR plus a range of 125 to 200 basis points, if drawn. There is a yearly commitment fee of 20 to 30 basis points, based on the Company’s secured net leverage ratio, charged on the unused portion of the Facility.
Contractual Obligations and Commitments
We have commitments under certain contractual arrangements to make future payments for goods and services. These contractual arrangements secure the rights to various assets and services to be used in the future in the normal course of business. We expect to fund these contractual arrangements with cash generated from operations in the normal course of business.
33
Item 3. Quantitative and Qualitative Disclosures about Market Risk
Interest Rate Risk
Our exposure to market rate risk for changes in interest rates primarily relates to our investment portfolio. We centrally manage our investment portfolios considering investment opportunities and risks, tax consequences, and overall financing strategies. Our investment portfolio includes fixed-income securities with a fair value of approximately $165.9 million at June 30, 2025. These securities are subject to interest rate risk and, based on our investment portfolio at June 30, 2025, a 100 basis point increase in interest rates would result in a decrease in the fair value of the portfolio of $1.0 million. While an increase in interest rates may reduce the fair value of the investment portfolio, we will not realize the losses in the Consolidated Statements of Operations unless the individual fixed-income securities are sold prior to recovery or the loss is determined to be other-than-temporary.
Currency Exchange Risk
We conduct business on a worldwide basis and, as such, a portion of our revenues, earnings, and net investments in foreign affiliates is exposed to changes in currency exchange rates. The economic impact of currency exchange rate movements is complex because such changes are often linked to variability in real growth, inflation, interest rates, governmental actions, and other factors. These changes, if material, could cause us to adjust our financing and operating strategies. Consequently, isolating the effect of changes in currency does not incorporate these other important economic factors.
Changes in currency exchange rates could affect our foreign currency denominated monetary assets and liabilities and forecasted cash flows. We may enter into monthly forward derivative contracts from time to time with the intent of mitigating a portion of this risk. We only use derivative financial instruments in the context of hedging and not for speculative purposes and have not historically designated our foreign exchange derivatives as hedges. Accordingly, changes in fair value from these contracts are recorded as “Other, net” in our Consolidated Statements of Operations. We execute derivative transactions with highly rated financial institutions to mitigate counterparty risk.
Our net sales to customers located outside of the United States represented approximately 87% and 86% of our total net sales for the three and six months ended June 30, 2025, respectively, 76% and 80% for the comparable 2024 period. We expect that net sales to customers outside the United States will continue to represent a large percentage of our total net sales. Our sales denominated in currencies other than the U.S. dollar represented approximately 5% and 6% of total net sales for the three and six months ended June 30, 2025, respectively, and 5% and 4% for the comparable 2024 period.
A 10% change in foreign exchange rates would have an immaterial impact on the consolidated results of operations since most of our sales outside the United States are denominated in U.S. dollars.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Our principal executive and financial officers have evaluated and concluded that our disclosure controls and procedures are effective as of June 30, 2025. The disclosure controls and procedures are designed to ensure that the information required to be disclosed in this report filed under the Securities Exchange Act of 1934 is recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and is accumulated and communicated to our principal executive and financial officers as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control Over Financial Reporting
During the quarter ended June 30, 2025, there were no changes in internal control that have materially affected or are reasonably likely to materially affect internal control over financial reporting.
34
PART II—OTHER INFORMATION
Item 1. Legal Proceedings
The Company is involved in various legal proceedings arising in the normal course of business. The Company does not believe that the ultimate resolution of these matters will have a material adverse effect on its consolidated financial position, results of operations, or cash flows.
Item 1A. Risk Factors
Information regarding risk factors appears in the Safe Harbor Statement at the beginning of this quarterly report on Form 10-Q, and in Part I — Item 1A of our 2024 Form 10-K, and Item 1A of our quarterly report on Form 10-Q for quarter ended March 31, 2025. There have been no material changes from the risk factors previously disclosed.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
None.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not Applicable.
Item 5. Other Information
During the fiscal quarter ended June 30, 2025, the following directors and Section 16 officers, as applicable, adopted, modified or terminated “Rule 10b5-1 trading arrangements" (as defined in Item 408 of Regulation S-K):
There were no “non-Rule 10b5-1 trading arrangements” (as defined in Item 408 of Regulation S-K)
35
Item 6. Exhibits
Unless otherwise indicated, each of the following exhibits has been filed with the Securities and Exchange Commission by Veeco under File No. 0-16244.
Exhibit | Incorporated by Reference | Filed or | ||||||||
Number |
| Exhibit Description |
| Form |
| Exhibit |
| Filing Date |
| Herewith |
10.1 | 8-K | 10.1 | 6/17/2025 | |||||||
10.2 | Veeco Amended and Restated Senior Executive Change in Control Policy, effective as of July 29, 2025. | * | ||||||||
31.1 | * | |||||||||
31.2 | * | |||||||||
32.1 | * | |||||||||
32.2 | * | |||||||||
101.INS | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | ** | ||||||||
101.XSD | XBRL Schema. | ** | ||||||||
101.PRE | XBRL Presentation. | ** | ||||||||
101.CAL | XBRL Calculation. | ** | ||||||||
101.DEF | XBRL Definition. | ** | ||||||||
101.LAB | XBRL Label. | ** | ||||||||
104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). | ** |
* Filed herewith
** Filed herewith electronically
36
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on August 6, 2025.
Veeco Instruments Inc. | |||
By: | /s/ WILLIAM J. MILLER, Ph.D. | ||
William J. Miller, Ph.D. | |||
Chief Executive Officer | |||
By: | /s/ JOHN P. KIERNAN | ||
John P. Kiernan | |||
Senior Vice President and Chief Financial Officer |
37